[微笑]_老虎社区_美港股上老虎

2021-11-10

[微笑]

Japan to pay $1.2 billion for 1.6 mln courses of Merck's COVID-19 pill<blockquote>日本将支付 12 亿美元购买 160 万个疗程的默克 COVID-19 药丸</blockquote>

免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":847708663,"tweetId":"847708663","gmtCreate":1636551884468,"gmtModify":1636551884553,"author":{"id":4087173810832020,"idStr":"4087173810832020","authorId":4087173810832020,"authorIdStr":"4087173810832020","name":"kiwicub","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":11,"crmLevelSwitch":0,"individualDisplayBadges":[],"wearingBadges":[],"fanSize":6,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"title":"","extraTitle":"","html":"<html><head></head><body><p><span>[微笑]&nbsp;</span></p></body></html>","htmlText":"<html><head></head><body><p><span>[微笑]&nbsp;</span></p></body></html>","text":"[微笑]","highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/847708663","repostId":1152344100,"repostType":4,"repost":{"id":"1152344100","kind":"news","pubTimestamp":1636550697,"share":"https://www.laohu8.com/m/news/1152344100?lang=zh_CN&edition=full","pubTime":"2021-11-10 21:24","market":"us","language":"en","title":"Japan to pay $1.2 billion for 1.6 mln courses of Merck's COVID-19 pill<blockquote>日本将支付 12 亿美元购买 160 万个疗程的默克 COVID-19 药丸</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1152344100","media":"Reuters","summary":"Nov 10 (Reuters) - Merck & Co Inc and partner Ridgeback Biotherapeutics said on Wednesday the Japane","content":"<p>Nov 10 (Reuters) - Merck &amp; Co Inc and partner Ridgeback Biotherapeutics said on Wednesday the Japanese government will pay about $1.2 billion for 1.6 million courses of their COVID-19 antiviral pill molnupiravir.</p><p><blockquote>路透 11 月 10 日 - 默克公司及其合作伙伴 Ridgeback Biotherapeutics 周三表示，日本政府将支付约 12 亿美元购买其 160 万个疗程的 COVID-19 抗病毒药物 molnupiravir。</blockquote></p><p> Countries have rushed to sign deals to buy molnupiravir, since data last month showed that when given early in the illness the drug could halve the chances of dying or being hospitalized for those most at risk of developing severe COVID-19.</p><p><blockquote>各国纷纷签署购买莫努匹拉韦的协议，因为上个月的数据显示，如果在疾病早期服用该药物，对于那些最有可能患严重新冠肺炎的人来说，死亡或住院的几率可以减半。</blockquote></p><p> Merck expects to make 10 million courses of treatment by the end of 2021, with at least 20 million courses to be produced in 2022.</p><p><blockquote>默克预计到 2021 年底将生产 1000 万个疗程，2022 年将生产至少 2000 万个疗程。</blockquote></p><p> If it gets authorization, molnupiravir, would be the first oral antiviral medication for COVID-19.</p><p><blockquote>如果获得授权，molnupiravir将成为第一个治疗新冠肺炎的口服抗病毒药物。</blockquote></p><p> On Tuesday, the U.S. government said it would buy another $1 billion worth of molnupiravir.</p><p><blockquote>周二，美国政府表示将再购买价值10亿美元的莫努匹拉韦。</blockquote></p><p></p>","source":"lsy1612507957220","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Japan to pay $1.2 billion for 1.6 mln courses of Merck's COVID-19 pill<blockquote>日本将支付 12 亿美元购买 160 万个疗程的默克 COVID-19 药丸</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nJapan to pay $1.2 billion for 1.6 mln courses of Merck's COVID-19 pill<blockquote>日本将支付 12 亿美元购买 160 万个疗程的默克 COVID-19 药丸</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">Reuters</strong><span class=\"h-time small\">2021-11-10 21:24</span>\n</p>\n</h4>\n</header>\n<article>\n<p>Nov 10 (Reuters) - Merck &amp; Co Inc and partner Ridgeback Biotherapeutics said on Wednesday the Japanese government will pay about $1.2 billion for 1.6 million courses of their COVID-19 antiviral pill molnupiravir.</p><p><blockquote>路透 11 月 10 日 - 默克公司及其合作伙伴 Ridgeback Biotherapeutics 周三表示，日本政府将支付约 12 亿美元购买其 160 万个疗程的 COVID-19 抗病毒药物 molnupiravir。</blockquote></p><p> Countries have rushed to sign deals to buy molnupiravir, since data last month showed that when given early in the illness the drug could halve the chances of dying or being hospitalized for those most at risk of developing severe COVID-19.</p><p><blockquote>各国纷纷签署购买莫努匹拉韦的协议，因为上个月的数据显示，如果在疾病早期服用该药物，对于那些最有可能患严重新冠肺炎的人来说，死亡或住院的几率可以减半。</blockquote></p><p> Merck expects to make 10 million courses of treatment by the end of 2021, with at least 20 million courses to be produced in 2022.</p><p><blockquote>默克预计到 2021 年底将生产 1000 万个疗程，2022 年将生产至少 2000 万个疗程。</blockquote></p><p> If it gets authorization, molnupiravir, would be the first oral antiviral medication for COVID-19.</p><p><blockquote>如果获得授权，molnupiravir将成为第一个治疗新冠肺炎的口服抗病毒药物。</blockquote></p><p> On Tuesday, the U.S. government said it would buy another $1 billion worth of molnupiravir.</p><p><blockquote>周二，美国政府表示将再购买价值10亿美元的莫努匹拉韦。</blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://finance.yahoo.com/news/1-japan-pay-1-2-131616365.html\">Reuters</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRK":"默沙东"},"source_url":"https://finance.yahoo.com/news/1-japan-pay-1-2-131616365.html","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1152344100","content_text":"Nov 10 (Reuters) - Merck & Co Inc and partner Ridgeback Biotherapeutics said on Wednesday the Japanese government will pay about $1.2 billion for 1.6 million courses of their COVID-19 antiviral pill molnupiravir.\nCountries have rushed to sign deals to buy molnupiravir, since data last month showed that when given early in the illness the drug could halve the chances of dying or being hospitalized for those most at risk of developing severe COVID-19.\nMerck expects to make 10 million courses of treatment by the end of 2021, with at least 20 million courses to be produced in 2022.\nIf it gets authorization, molnupiravir, would be the first oral antiviral medication for COVID-19.\nOn Tuesday, the U.S. government said it would buy another $1 billion worth of molnupiravir.","news_type":1,"symbols_score_info":{"MRK":0.9}},"isVote":1,"tweetType":1,"viewCount":2817,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":6,"xxTargetLangEnum":"ZH_CN"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/847708663"}